Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Launched by MAYO CLINIC · Nov 22, 2023

Keywords

ClinConnect Summary

The HALT Study is looking at how to manage high blood pressure in patients with certain types of B-cell cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma, who are starting treatment with a medication called Bruton tyrosine kinase inhibitors (BTKis). This study aims to understand how often new high blood pressure occurs and how to best take care of it in these patients. If you or a loved one has one of these cancers and is beginning BTKi treatment, you may be eligible to participate in this study, as long as there is no involvement of the central nervous system in the cancer.

Participants in the study will visit the Mayo Clinic for regular check-ups and follow-ups during their treatment. This is a great opportunity to help improve care for future patients while also receiving close monitoring for any changes in blood pressure. The study is currently recruiting participants of all ages and genders, so if you think you might qualify, it could be worth discussing with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up
• Exclusion Criteria:
• • Patients with known central nervous system (CNS) involvement of their B-cell malignancy